OBJECTIVE: To describe prostate cancer treatment decision making, focusing on knowledge and attitudes toward observation, known as watchful waiting (WW) or active surveillance (AS), and reasons for not choosing WW/AS. METHODS: Semistructured in-person interviews were conducted with 21 men (14 black; 7 white) with recently diagnosed localized prostate cancer. RESULTS: All cancers were detected by prostate-specific antigen screening; 14 men had low-risk disease. Nineteen chose surgery or radiation treatment. The majority wanted to "get rid of" or "cure" the cancer by undergoing aggressive therapy, even with awareness of the potential for significant side effects. Most men seemed unaware of the uncertainty/controversies that aggressive treatment may not cure their cancer or improve their survival. Limited knowledge about WW/AS was common, and few remembered WW/AS being presented as a viable option. Rather, many men perceived it as "doing nothing." Some men, who initially were inclined toward WW/AS, yielded to pressure from family, physicians, or both to choose aggressive treatment. Lack of physician support was a significant barrier to WW/AS. CONCLUSIONS: The observational strategy (WW/AS) was not viewed as a reasonable approach, even for those with low-risk cancer. The desire for aggressive therapy may reflect the complex psychology associated with receiving a diagnosis of cancer and the limited supportive counseling received. Further efforts to better understand and educate patients and physicians may help men make informed and appropriate treatment decisions to maximize quality of life without compromising survival.
OBJECTIVE: To describe prostate cancer treatment decision making, focusing on knowledge and attitudes toward observation, known as watchful waiting (WW) or active surveillance (AS), and reasons for not choosing WW/AS. METHODS: Semistructured in-person interviews were conducted with 21 men (14 black; 7 white) with recently diagnosed localized prostate cancer. RESULTS: All cancers were detected by prostate-specific antigen screening; 14 men had low-risk disease. Nineteen chose surgery or radiation treatment. The majority wanted to "get rid of" or "cure" the cancer by undergoing aggressive therapy, even with awareness of the potential for significant side effects. Most men seemed unaware of the uncertainty/controversies that aggressive treatment may not cure their cancer or improve their survival. Limited knowledge about WW/AS was common, and few remembered WW/AS being presented as a viable option. Rather, many men perceived it as "doing nothing." Some men, who initially were inclined toward WW/AS, yielded to pressure from family, physicians, or both to choose aggressive treatment. Lack of physician support was a significant barrier to WW/AS. CONCLUSIONS: The observational strategy (WW/AS) was not viewed as a reasonable approach, even for those with low-risk cancer. The desire for aggressive therapy may reflect the complex psychology associated with receiving a diagnosis of cancer and the limited supportive counseling received. Further efforts to better understand and educate patients and physicians may help men make informed and appropriate treatment decisions to maximize quality of life without compromising survival.
Authors: Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey Journal: J Gen Intern Med Date: 2004-02 Impact factor: 5.128
Authors: W Demark-Wahnefried; J M Schildkraut; C E Iselin; E Conlisk; A Kavee; T E Aldrich; E J Lengerich; P J Walther; D F Paulson Journal: Cancer Date: 1998-07-15 Impact factor: 6.860
Authors: Karen E Hoffman; Jiangong Niu; Yu Shen; Jing Jiang; John W Davis; Jeri Kim; Deborah A Kuban; George H Perkins; Jay B Shah; Grace L Smith; Robert J Volk; Thomas A Buchholz; Sharon H Giordano; Benjamin D Smith Journal: JAMA Intern Med Date: 2014-09 Impact factor: 21.873
Authors: Ronald E Myers; Amy E Leader; Jean Hoffman Censits; Edouard J Trabulsi; Scott W Keith; Anett M Petrich; Anna M Quinn; Robert B Den; Mark D Hurwitz; Costas D Lallas; Sarah E Hegarty; Adam P Dicker; Charnita M Zeigler-Johnson; Veda N Giri; Hasan Ayaz; Leonard G Gomella Journal: J Cancer Educ Date: 2018-02 Impact factor: 2.037
Authors: Gregory B Auffenberg; Khurshid R Ghani; Shreyas Ramani; Etiowo Usoro; Brian Denton; Craig Rogers; Benjamin Stockton; David C Miller; Karandeep Singh Journal: Eur Urol Date: 2018-10-11 Impact factor: 20.096
Authors: Richard M Hoffman; Tania Lobo; Stephen K Van Den Eeden; Kimberly M Davis; George Luta; Amethyst D Leimpeter; David Aaronson; David F Penson; Kathryn Taylor Journal: Med Decis Making Date: 2019-10-21 Impact factor: 2.583
Authors: Betina Yanez; Natalie E Bustillo; Michael H Antoni; Suzanne C Lechner; Jason Dahn; Bruce Kava; Frank J Penedo Journal: J Behav Med Date: 2014-09-19
Authors: Kathleen D Lyons; Hsin H Li; Emily M Mader; Telisa M Stewart; Christopher P Morley; Margaret K Formica; Scott D Perrapato; John D Seigne; Elias S Hyams; Brian H Irwin; Terry Mosher; Mark T Hegel Journal: Am J Mens Health Date: 2016-07-07
Authors: Scott P Kelly; Stephen K Van Den Eeden; Richard M Hoffman; David S Aaronson; Tania Lobo; George Luta; Amethyst D Leimpter; Jun Shan; Arnold L Potosky; Kathryn L Taylor Journal: J Urol Date: 2016-04-14 Impact factor: 7.450
Authors: Jinping Xu; James Janisse; Julie J Ruterbusch; Joel Ager; Joe Liu; Margaret Holmes-Rovner; Kendra L Schwartz Journal: Ann Fam Med Date: 2016-05 Impact factor: 5.166